This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Artios Pharma Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Mark Charles: Innovator in Cancer Treatment
Introduction
Mark Charles is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of heterocyclic compounds. His work focuses on creating effective solutions for the treatment and prophylaxis of cancer.
Latest Patents
Mark Charles holds a patent for "Heterocyclic compounds for use in the treatment of cancer." This application relates to heterocyclic amide derivatives and their use in combating cancer. It also includes compositions containing these derivatives and the processes for their preparation. He has 1 patent to his name, showcasing his commitment to advancing medical science.
Career Highlights
Mark is currently employed at Artios Pharma Limited, where he continues to push the boundaries of cancer research. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking advancements in treatment options.
Collaborations
Throughout his career, Mark has worked alongside talented individuals such as Peter Blencowe and Tennyson Ekwuru. These collaborations have enriched his research and fostered a dynamic environment for innovation.
Conclusion
Mark Charles exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. His dedication to research and development is evident in his patent and ongoing work at Artios Pharma Limited.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile